Relapsed or Refractory LBCL After One Line of Therapy
Study 1
A randomized, open-label, multicenter trial evaluated the efficacy of BREYANZI in adult patients with relapsed or refractory LBCL after first-line chemoimmunotherapy (Study 1: JCAR017-BCM-003; NCT03575351). Patients had not yet received treatment for relapsed or refractory lymphoma, were potential candidates for autologous HSCT, and were required to have primary refractory disease or relapse within 12 months from complete response (CR) to initial chemoimmunotherapy. Eligibility criteria required adequate organ function and blood counts for HSCT.
In total, 184 patients were randomized in a 1:1 ratio to receive a single infusion of BREYANZI (planned dose, 100 × 106 CAR-positive viable T cells) or to receive standard therapy consisting of 3 cycles of chemoimmunotherapy followed by high-dose therapy and autologous HSCT in patients who attained CR or PR. All patients underwent leukapheresis prior to randomization.
Patients randomized to BREYANZI were to receive lymphodepleting chemotherapy consisting of fludarabine 30 mg/m2/day and cyclophosphamide 300 mg/m2/day concurrently for 3 days followed by BREYANZI infusion 2 to 7 days after completion of lymphodepleting chemotherapy. Bridging chemotherapy was permitted between leukapheresis and the start of lymphodepleting chemotherapy. BREYANZI was administered in the inpatient (79%) and outpatient (21%) setting.
In the overall study population, the median age was 59 years (range: 20 to 75 years), 57% were male, 59% were White, 10% were Asian, and 4% were Black. Diagnoses included de novo DLBCL NOS (55%), high-grade B-cell lymphoma (23%), primary mediastinal large B-cell lymphoma (10%), and DLBCL arising from indolent lymphoma (8%). Of these patients, 73% had primary refractory disease to last therapy and 27% had relapsed disease within 12 months of achieving CR to first-line therapy.
Of 92 patients randomized to receive BREYANZI, 89 (97%) received BREYANZI. The median time from leukapheresis to product availability was 26 days (range: 19 to 84 days), and the median time from leukapheresis to product infusion was 36 days (range: 25 to 91 days). Fifty-eight (63%) patients received bridging therapy. One patient received a nonconforming product (manufacturing failure; 1.1%).
Of the 92 patients randomized to receive standard therapy, 91 started treatment and 43 (47%) received high-dose therapy and HSCT. The most common reason for not receiving HSCT was lack of efficacy of the salvage chemotherapy.
The primary efficacy measure was event-free survival (EFS) as determined by an independent review committee (IRC). Other efficacy measures included progression-free survival. Efficacy is summarized in Table 18 and Figure 1. The estimated 1-year EFS was 45% [95% CI: 29, 59] in the BREYANZI arm and 24% [95% CI: 14, 35] in the standard therapy arm.
Of the 92 patients in the BREYANZI arm, the estimated median duration of response (DOR) was not reached (95% CI: 7.9 months, NR) in patients who achieved CR (N=61) and 2.3 months (95% CI: 2.1, NR) in patients who achieved a best response of PR (N=18).
An interim analysis of overall survival was conducted at the time of the primary EFS analysis. The interim analysis of overall survival did not meet the criteria for statistical significance. Forty-six patients randomized to the standard therapy arm (50%) subsequently received BREYANZI on protocol.
Table 18: Efficacy Results in Patients with Relapsed or Refractory LBCL (Study 1)| NR=not reached; CI=confidence interval. |
| a Per the Lugano criteria, as assessed by an IRC. |
| b EFS is defined as time from randomization to the earliest date of disease progression or relapse, death from any cause, failure to achieve CR or PR by 9 weeks post-randomization, or start of new lymphoma therapy due to efficacy concerns. |
| c Kaplan-Meier estimate. |
| d Based on a stratified Cox proportional hazards model. For all stratified analyses, stratification was based on response to first-line therapy (primary refractory vs relapsed) and second-line age-adjusted International Prognostic Index. |
| e Cochran-Mantel-Haenszel test. |
| f p-value is compared with 0.012 of the allocated alpha for this pre-specified interim analysis. |
Outcomea | BREYANZI Arm (N=92) | Standard Therapy Arm (N=92) |
Event-Free Survivalb |
Number of events, n (%) | 35 (38) | 63 (69) |
Median, months [95% CI]c | 10.1 [6.1, NR] | 2.3 [2.2, 4.3] |
Hazard ratio [95% CI]d | 0.34 [0.22, 0.52] |
One-sided p-value | <0.0001f |
Complete Response Rate, % [95% CI] | 66 [56, 76] | 39 [29, 50] |
Difference in CR rate, % [95% CI] | 27 [12, 41] |
One-sided p-valuee | <0.0001f |
Progression-Free Survival |
Number of events, n (%) | 28 (30) | 43 (47) |
Median, months [95% CI]c | 14.8 [6.6, NR] | 5.7 [3.9, 9.4] |
Hazard ratio [95% CI]d | 0.41 [0.25, 0.66] |
One-sided p-value | 0.0001f |
Figure 1: Kaplan-Meier Plot of IRC-Assessed Event-Free Survival (Intention-to- Treat Analysis)
Fig_transform_graph (Fig Transform Graph)
Study 2
The efficacy of BREYANZI was evaluated in a single-arm, open-label, multicenter trial (Study 2: 017006; NCT03483103) in transplant-ineligible patients with relapsed or refractory LBCL after one line of chemoimmunotherapy. The study enrolled patients who were not eligible for high-dose therapy and autologous HSCT due to organ function or age, while also having adequate organ function for CAR-T cell therapy. The study required at least one of the following criteria: age ≥ 70 years, adjusted diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 60%; LVEF < 50%; creatinine clearance < 60 mL/min; AST or ALT greater than 2 × ULN, or ECOG performance status of 2. The planned dose of BREYANZI was 100 × 106 CAR-positive viable T cells. Bridging therapy for disease control was permitted between leukapheresis and the start of lymphodepleting chemotherapy. Of the 61 patients treated with BREYANZI, 32 (53%) received bridging therapy.
BREYANZI was administered 2 to 7 days following completion of lymphodepleting chemotherapy. The lymphodepleting chemotherapy regimen consisted of fludarabine 30 mg/m2/day and cyclophosphamide 300 mg/m2/day concurrently for 3 days. BREYANZI was administered in the inpatient (67%) and outpatient (33%) setting.
Of 74 patients who underwent leukapheresis, 61 (82%) received BREYANZI and comprise the main efficacy population; 1 (1.4%) received CAR-positive T cells that did not meet the product specifications for BREYANZI (manufacturing failure); and 12 (16%) did not receive CAR-positive T cells for other reasons.
Of the 61 patients who received BREYANZI, the median age was 74 years (range: 53 to 84 years), 61% were male, 89% were White, 3% were Asian, and 2% were Black. Diagnoses included de novo DLBCL NOS (51%), high-grade B-cell lymphoma (33%), and DLBCL arising from follicular lymphoma (15%). Of these patients, 53% had primary refractory disease, 23% had relapse within 12 months of completing first-line therapy, and 25% had relapse >12 months after first-line therapy.
Efficacy was based on CR rate and DOR, as determined by an independent review committee (IRC) using 2014 Lugano criteria (Tables 19 and 20). The median time to CR was 1 month (range 0.8 to 6.9 months).
Table 19: Response Rate in Relapsed or Refractory LBCL (Study 2)| CI=confidence interval. |
| a Per the Lugano criteria, as assessed by an IRC. |
| b 2-sided 95% exact Clopper-Pearson confidence intervals. |
Outcomea | BREYANZI-Treated (N=61) | All Leukapheresed (N=74) |
Overall Response, n (%) [95% CI]b | 49 (80%) [68%, 89%] | 50 (68%) [56%, 78%] |
Complete Response [95% CI] | 33 (54%) [41%, 67%] | 34 (46%) [34%, 58%] |
Partial Response [95% CI] | 16 (26%) [16%, 39%] | 16 (22%) [13%, 33%] |
Table 20: Duration of Response in Study 2| DOR=duration of response; CI=confidence interval; CR=complete response; PR=partial response; NR=not reached. |
| a Per the Lugano criteria, as assessed by an IRC. |
| b Kaplan-Meier method is used to obtain 2-sided 95% confidence intervals. |
| c Kaplan-Meier estimate. |
| + Indicates a censored value. |
Outcomea | BREYANZI-Treated (N=61) |
Number of Responders | 49 |
DOR |
Median [95% CI], months b Range, months | 11.2 [5.1, NR] 0.0+ to 22.8+ |
DOR if Best Response is CR Median [95% CI], months Range, months Rate at 6 months [95% CI] c Rate at 12 months [95% CI] c | NR [11.2, NR] 2.0+ to 22.8+ 83% [64, 93] 68% [45, 83] |
DOR if Best Response is PR |
Median [95% CI], months | 2.1 [1.4, 2.3] |
Range, months | 0.0+ to 7.9 |
Rate at 6 months [95% CI] c | 8.2% [0.5, 30.5] |
Relapsed or Refractory LBCL After Two or More Lines of Therapy
The efficacy of BREYANZI was evaluated in an open-label, multicenter, single-arm trial (Study 3 - LBCL Cohort: 017001; NCT02631044) in adult patients with relapsed or refractory large B-cell non-Hodgkin lymphoma after at least 2 lines of therapy. The study included patients with ECOG performance status ≤ 2, prior autologous and/or allogeneic HSCT, and secondary CNS lymphoma involvement. The study excluded patients with a creatinine clearance of less than 30 mL/min, ALT > 5 times the ULN, or LVEF < 40%. There was no prespecified threshold for blood counts; patients were eligible to enroll if they were assessed by the investigator to have adequate bone marrow function to receive lymphodepleting chemotherapy. Bridging therapy for disease control was permitted between apheresis and the start of lymphodepleting chemotherapy, including intrathecal chemotherapy or radiation therapy for treatment of CNS involvement with lymphoma.
BREYANZI was administered 2 to 7 days following completion of lymphodepleting chemotherapy. The lymphodepleting chemotherapy regimen consisted of fludarabine 30 mg/m2/day and cyclophosphamide 300 mg/m2/day concurrently for 3 days. BREYANZI was administered in the inpatient and outpatient setting.
Of 299 patients who underwent leukapheresis for whom BREYANZI was manufactured in the dose range of 50 to 110 × 106 CAR-positive viable T cells:
- 44 (15%) did not receive CAR-positive T cells either due to manufacturing failures (n=2), death (n=29), disease complications (n=6), or other reasons (n=7).
- 204 (68%) received BREYANZI in the intended dose range, of whom 192 were evaluable for efficacy (main efficacy population); 12 were not evaluable due to absence of PET positive disease at study baseline or after bridging therapy.
- 51 (17%) either received BREYANZI outside of the intended dose range (n=26) or received CAR-positive T cells that did not meet the product specifications for BREYANZI (manufacturing failures; n=25).
Of the 192 patients in the main efficacy population, the median age was 63 years (range: 18 to 86 years), 69% were male, 84% were White, 6% were Black, and 4.7% were Asian. The median number of prior therapies was 3 (range: 1 to 8). Diagnoses were de novo DLBCL (53%), DLBCL transformed from indolent lymphoma (25%), high-grade B-cell lymphoma (14%), primary mediastinal large B-cell lymphoma (7%), follicular lymphoma, grade 3B (1.0%). Of these patients, 64% had disease refractory to last therapy, 53% had primary refractory disease, 37% had prior HSCT and 2.6% had CNS involvement.
Efficacy was based on CR rate and DOR, as determined by an IRC using 2014 Lugano criteria (Tables 21 and 22). The median time to first response (CR or partial response [PR]) was 1.0 month (range: 0.7 to 8.9 months). The median time to first CR was 1.0 month (range 0.8 to 12.5 months). Of the 104 patients who achieved CR, 23 initially had stable disease (6 patients) or PR (17 patients), with a median time to improvement of 2.2 months (range: 0.7 to 11.6 months).
Table 21: Response Rate in Main Efficacy Population (Study 3 - LBCL Cohort)| CI=confidence interval. |
| a Per the Lugano criteria, as assessed by an IRC. |
| BREYANZI-Treated N=192 |
Overall Response Ratea, n [95% CI] | 141 (73%) [67%, 80%] |
Complete Response, n [95% CI] | 104 (54%) [47%, 61%] |
Partial Response, n [95% CI] | 37 (19%) [14%, 26%] |
Table 22: Duration of Response in Study 3 - LBCL Cohort| DOR=duration of response; CI=confidence interval; CR=complete response; PR=partial response; NR=not reached. |
| a Evaluable for efficacy. |
| b KM method was used to obtain 2-sided 95% confidence intervals. |
| + Indicates a censored value. |
| BREYANZI-Treateda N=192 |
Number of Responders | 141 |
DOR (Months) | |
Median [95% CI]b Range | 16.7 [5.3, NR] 0.0+ to 23.5+ |
DOR if Best Response is CR (Months) | |
Median [95% CI] Range | NR [16.7, NR] 0.7+ to 23.5+ |
DOR if Best Response is PR (Months) | |
Median [95% CI] Range | 1.4 [1.1, 2.2] 0.0+ to 22.8+ |
Response durations were longer in patients who achieved a CR, as compared to patients with a best response of PR (Table 22). Of the 104 patients who achieved CR, 68 (65%) had remission lasting at least 6 months and 64 (62%) had remission lasting at least 9 months.
Of the 287 patients who underwent leukapheresis and had radiographically evaluable disease, 27 additional patients achieved a response, apart from the responses noted in Table 21. The IRC-assessed overall response rate in the leukapheresed population (n=287) was 59% (95% CI: 53, 64), with a CR rate of 43% (95% CI: 37, 49) and PR rate of 15% (95% CI: 11, 20). These efficacy results include responses that may have been contributed solely by bridging therapy, responses after receipt of product outside of the intended dose range, and responses to product that did not meet release specifications.